Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...
emjreviews.com2d
Inhalation Innovation: Phase IIb Study Design of Inhaled Pirfenidone in the Treatment of Progressive Pulmonary Fibrosis
Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
emjreviews.com2d
Heterogeneity of Inflammatory Processes and Pathways Driving Chronic Obstructive Pulmonary Disease Pathology
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Paige Mahaney, Ph.D. Chief Scientific Officer Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience ...
BioPharma Dive2d
Oral version of Novo diabetes drug protects heart health in large study
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
C4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific ...